Interestingly, in murine tumor models, it was shown that anti-PD-1 monoclonal antibody (mAb) therapy rapidly removed from PD-1+ CD8+ T cells and transferred to neighboring PD-1 negative TAMs, which could be reversed by the blockage of the Fc/FcγR binding that eventually amplifies anti-PD-1 therapeutic efficacy [20]. The gene discussed is CD8A; the disease is neoplasm.